DENOSUMAB
Overview
Denosumab is a human monoclonal antibody (IgG2) that targets and bind with hiogh affinity and specificity to RANK-L, Preventing activation of its receptors, rank, on the surface of osteolast precursorss and osteoclast, in this way it inhibits ostoclast formation, function and survival, thereby decreasing bone resorption in cortical and trabecular bone, it is used for the treatment of osteoporosis. in post menopausal women. and in men with prostate cancer reciveing hormone ablation.
Categories
- 2 Analgesics, antipyretics, NSAIDs, antigout, and antirheumatics
Primary Characterstics
Indications
Back to top
Pharmacokinetics
Back to top
Contraindications
Back to top
Back to top
Side Effects
Back to top
Dosage
DENOSUMAB's dosage details are as follows:
| Dose
|
Single Dose
|
Frequency
|
Route
|
Instructions
|
Adult Dosage
|
| 60 mg | 60 (60) | As recommended. | S/C | given every 6 months |
Paedriatic Dosage (20kg)
|
| | | | |
Neonatal Dosage (3kg)
|
| No data regarding the neonatal dosage details of DENOSUMAB is available. |
High Risk Groups
Back to top
Warning / Precautions
Back to top
Storage Conditions
Back to top
Interference in Pathology
Back to top
Brands / Trade Names of
DENOSUMAB
Back to top
Previous Drug Generic - Next Drug Generic